Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - sucroferric oxyhydroxide, quantity: 2500 mg - tablet, chewable - excipient ingredients: colloidal anhydrous silica; neohesperidin-dihydrochalcone; magnesium stearate; flavour - velphoro is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease (ckd) on dialysis.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - sucroferric oxyhydroxide, quantity: 2500 mg - tablet, chewable - excipient ingredients: colloidal anhydrous silica; neohesperidin-dihydrochalcone; magnesium stearate; flavour - velphoro is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease (ckd) on dialysis.

İsrail - İngilizce - Ministry of Health

cts ltd - iron as sucroferric oxyhydroxide - chewable tablets - iron as sucroferric oxyhydroxide 500 mg - sucroferric oxyhydroxide - velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (ckd) patients on haemodialysis (hd) or peritoneal dialysis (pd).velphoro should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues, or calcimimetics to control the development of renal bone disease.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ferric carboxymaltose 180mg equivalent to iron 50mg - solution for injection - 50 mg/ml - active: ferric carboxymaltose 180mg equivalent to iron 50mg excipient: hydrochloric acid sodium hydroxide water for injection - indicated for the treatment of iron deficiency when oral iron preparations are ineffective, oral preparations cannot be used or there is a clinical need to deliver iron rapidly.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 185 mg/ml (equivalent: iron, qty 50 mg/ml) - oral liquid - excipient ingredients: sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; purified water; sucrose; sodium hydroxide; flavour - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.,prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 37 mg/ml (equivalent: iron, qty 10 mg/ml) - oral liquid - excipient ingredients: propyl hydroxybenzoate; purified water; sorbitol solution (70 per cent) (non-crystallising); ethanol; sucrose; sodium hydroxide; methyl hydroxybenzoate; flavour - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - iron polymaltose, quantity: 370 mg (equivalent: iron, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; macrogol 6000; crospovidone; magnesium stearate; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron polymaltose 370mg equivalent to iron 100mg - film coated tablet - 100 mg - active: iron polymaltose 370mg equivalent to iron 100mg excipient: crospovidone macrogol 6000 magnesium stearate microcrystalline cellulose opadry maroon oy-s-36413 - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron polymaltose 37 mg/ml equivalent to iron 10mg/ml - syrup - 10 mg/ml - active: iron polymaltose 37 mg/ml equivalent to iron 10mg/ml excipient: cream flavour 225082 ethanol methyl hydroxybenzoate propyl hydroxybenzoate purified water sodium hydroxide sorbitol sucrose - treatment of iron deficiency in adults and adolescents where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate. prevention of iron deficiency in adults and adolescents at high risk where the use of ferrous iron supplements is not tolerated, or otherwise inappropriate.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - iron polymaltose 50 mg/ml (159mg/ml iron hydroxide polymaltose complex =50mg/ml iron) - solution for injection - 100mg/2ml - active: iron polymaltose 50 mg/ml (159mg/ml iron hydroxide polymaltose complex =50mg/ml iron) excipient: hydrochloric acid sodium hydroxide water for injection - for the prevention and treatment of iron deficiency anaemia in the following circumstances: · when oral therapy is contraindicated · when enteric absorption of iron is defective · when patient non-compliance or persistent gastrointestinal intolerance makes oral therapy impractical · treating iron deficiency anaemia of prematurity and that occurring in geriatric patients · treating iron deficiency states discovered in the third trimester of pregnancy · anaemia resulting from excessive blood loss · where contact between the doctor and patient occurs at irregular intervals